Skip to main content
Erschienen in: International Journal of Hematology 2/2012

01.02.2012 | Case Report

Interleukin-6-producing dermoid cyst associated with multicentric Castleman’s disease

verfasst von: Shigeyuki Ebara, Soken-Nakazawa J. Song, Hiroyuki Mizuta, Yasushi Ito, Kenji Hasegawa, Tsuneko Kamata, Teppei Matsumura-Nishikawa, Takafumi Ogawa, Jyunichi Soneda, Kazuyuki Yoshizaki

Erschienen in: International Journal of Hematology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Dysregulated overproduction of interleukin-6 (IL-6) from activated B cells in affected lymph nodes has been implicated in the pathogenesis of multicentric Castleman’s disease (MCD), a rare lymphoproliferative disorder accompanied by systemic manifestations. We here report the case of a 32-year-old female presenting with MCD associated with a dermoid cyst in the pelvic cavity. The co-occurrence of MCD and dermoid cyst has not been reported before. Immunohistochemical analysis of the tissue sections showed IL-6 production in CD68-positive macrophage cells, which had infiltrated the dermoid cyst. Removal of the cyst resulted in partial improvement in systemic symptoms accompanied by a decrease in serum IL-6, while complete improvement was obtained by treatment with an anti-IL-6 receptor antibody following resection of the dermoid cyst. To the best of our knowledge, this is the first study to provide evidence of IL-6 production by CD68+ cells in a dermoid cyst involved in MCD.
Literatur
1.
Zurück zum Zitat Castleman B, Iverson L, Menendze VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–30.PubMedCrossRef Castleman B, Iverson L, Menendze VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–30.PubMedCrossRef
2.
Zurück zum Zitat Keller AR, Hochholzer L, Castleman B. Hyalin-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670–83.PubMedCrossRef Keller AR, Hochholzer L, Castleman B. Hyalin-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670–83.PubMedCrossRef
3.
Zurück zum Zitat Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3:1202–16.PubMed Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3:1202–16.PubMed
4.
Zurück zum Zitat Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Lee T, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castelman’s disease. Blood. 1989;74:1360–7.PubMed Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Lee T, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castelman’s disease. Blood. 1989;74:1360–7.PubMed
5.
Zurück zum Zitat Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castelman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMed Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castelman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMed
6.
Zurück zum Zitat Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman’s disease. Blood. 2005;106:2627–32.PubMedCrossRef Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman’s disease. Blood. 2005;106:2627–32.PubMedCrossRef
7.
Zurück zum Zitat Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116:3627–34.PubMedCrossRef Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116:3627–34.PubMedCrossRef
8.
Zurück zum Zitat Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32:1006–12.PubMedCrossRef Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32:1006–12.PubMedCrossRef
9.
Zurück zum Zitat Molinié V, Diebold J. Hodgkin’s disease associated with localized or multicentric Castleman’s disease. Arch Pathol Lab Med. 1995;119:201.PubMed Molinié V, Diebold J. Hodgkin’s disease associated with localized or multicentric Castleman’s disease. Arch Pathol Lab Med. 1995;119:201.PubMed
10.
Zurück zum Zitat Larroche C, Cacoub P, Soulier J, Oksenhendler E, Clauvel JP, Piette JC, et al. Castleman’s disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69:119–26.PubMedCrossRef Larroche C, Cacoub P, Soulier J, Oksenhendler E, Clauvel JP, Piette JC, et al. Castleman’s disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69:119–26.PubMedCrossRef
11.
Zurück zum Zitat Curioni S, D’Amico M, Quartagno R, Martino S, Dell’Antonio G, Cusi D. Castleman’s disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant. 2001;16:1475–8.PubMedCrossRef Curioni S, D’Amico M, Quartagno R, Martino S, Dell’Antonio G, Cusi D. Castleman’s disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant. 2001;16:1475–8.PubMedCrossRef
12.
Zurück zum Zitat Tavoni A, Vitali C, Baglioni P, Gerli R, Marchetti G, Di Munno O, et al. Multicentric Castleman’s disease in a patient with primary Sjögren’s syndrome. Rheumatol Int. 1993;12:251–3.PubMedCrossRef Tavoni A, Vitali C, Baglioni P, Gerli R, Marchetti G, Di Munno O, et al. Multicentric Castleman’s disease in a patient with primary Sjögren’s syndrome. Rheumatol Int. 1993;12:251–3.PubMedCrossRef
13.
Zurück zum Zitat Nanki T, Tomiyama J, Arai S. Mixed connective tissue disease associated with multicentric Castleman’s disease. Scand J Rheumatol. 1994;23:215–7.PubMedCrossRef Nanki T, Tomiyama J, Arai S. Mixed connective tissue disease associated with multicentric Castleman’s disease. Scand J Rheumatol. 1994;23:215–7.PubMedCrossRef
14.
Zurück zum Zitat Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, et al. Interleukin-6 gene expression in Castleman’s disease. Blood. 1991;78:2923–30.PubMed Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, et al. Interleukin-6 gene expression in Castleman’s disease. Blood. 1991;78:2923–30.PubMed
15.
Zurück zum Zitat Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.PubMedCrossRef Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.PubMedCrossRef
16.
Zurück zum Zitat Zaloude KC. Tumors of ovary. In: Fletcher CDM, editor. Diagnostic histopathology of tumours. 2nd ed. Churchill Livingston: Harcourt Publication Ltd; 2000. p. 611. Zaloude KC. Tumors of ovary. In: Fletcher CDM, editor. Diagnostic histopathology of tumours. 2nd ed. Churchill Livingston: Harcourt Publication Ltd; 2000. p. 611.
17.
Zurück zum Zitat Van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia. 2003;17:2257–317.PubMedCrossRef Van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia. 2003;17:2257–317.PubMedCrossRef
18.
Zurück zum Zitat Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–64.PubMedCrossRef Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–64.PubMedCrossRef
19.
Zurück zum Zitat Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1–10.PubMed Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1–10.PubMed
20.
Zurück zum Zitat Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol. 2008;180:3492–501.PubMed Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol. 2008;180:3492–501.PubMed
Metadaten
Titel
Interleukin-6-producing dermoid cyst associated with multicentric Castleman’s disease
verfasst von
Shigeyuki Ebara
Soken-Nakazawa J. Song
Hiroyuki Mizuta
Yasushi Ito
Kenji Hasegawa
Tsuneko Kamata
Teppei Matsumura-Nishikawa
Takafumi Ogawa
Jyunichi Soneda
Kazuyuki Yoshizaki
Publikationsdatum
01.02.2012
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2012
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0978-5

Weitere Artikel der Ausgabe 2/2012

International Journal of Hematology 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.